Literature DB >> 23179579

Population pharmacokinetic analysis during the first 2 years of life: an overview.

Amélie Marsot1, Audrey Boulamery, Bernard Bruguerolle, Nicolas Simon.   

Abstract

Three decades after its introduction, pharmacokinetic population approaches have become a reference method for drug modelling, particularly in paediatrics. The main practical limitation in this specific population is the collected blood volume. Pharmacokinetic population approaches using sparse sampling may resolve this issue. The pharmacokinetics of many drugs have been studied during the last 25 years using such methods. This review summarizes all of the published studies concerning population pharmacokinetic approaches in paediatric subjects from neonate to 2 years old. A literature search was conducted using the PubMed database, from 1985 to December 2010, using the following terms: pharmacokinetic(s), population, paediatric/pediatric and neonate(s). Articles were excluded if they were not pertinent according to our criteria. References of all relevant articles were also evaluated. Ninety-eight studies were included in this review. The following information was extracted from the articles: drug name, therapeutic class, population size, age of patients, number of samples per patient, covariates used for clearance and volume of distribution estimates, software used for modelling and validation methods. An increasing rate of publications over the years was observed; 44 different drugs were studied using a pharmacokinetic population approach. Antibacterials were the most studied class of drugs, including a large number of studies devoted to vancomycin and gentamicin. It must be underlined that few studies have been performed on anticonvulsant drugs and anaesthetics used in clinical daily practice conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179579     DOI: 10.1007/s40262-012-0015-8

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  112 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity.

Authors:  T C Lee; B Charles; P Steer; V Flenady; A Shearman
Journal:  Clin Pharmacol Ther       Date:  1997-06       Impact factor: 6.875

3.  Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants.

Authors:  E Yukawa; F Suematsu; M Yukawa; M Minemoto
Journal:  J Clin Pharm Ther       Date:  2005-04       Impact factor: 2.512

4.  Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia.

Authors:  Charlotte van Kesteren; Manon J N L Benders; Floris Groenendaal; Frank van Bel; F F Tessa Ververs; Carin M A Rademaker
Journal:  Ther Drug Monit       Date:  2006-06       Impact factor: 3.681

5.  Population pharmacokinetics of cefepime in the neonate.

Authors:  Edmund Capparelli; Christine Hochwald; Maynard Rasmussen; Amy Parham; John Bradley; Fernando Moya
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.

Authors:  Sihem Benaboud; Didier K Ekouévi; Saik Urien; Elisabeth Rey; Elise Arrivé; Stéphane Blanche; Glenda Gray; Kruy Leang Sim; Divine Avit; James McIntyre; Eric Nerrienet; François Dabis; Jean-Marc Tréluyer; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

7.  Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures.

Authors:  Mohammed Al Za'abi; Anders Lanner; Xiao Xiaonian; Timothy Donovan; Bruce Charles
Journal:  Ther Drug Monit       Date:  2006-12       Impact factor: 3.681

8.  Population pharmacokinetics of ibuprofen enantiomers in very premature neonates.

Authors:  Nicolas Gregoire; Virginie Gualano; Anne Geneteau; Laurette Millerioux; Murielle Brault; Alain Mignot; Jean-Christophe Roze
Journal:  J Clin Pharmacol       Date:  2004-10       Impact factor: 3.126

9.  A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates.

Authors:  Robert DiCenzo; Alan Forrest; Judianne C Slish; Carol Cole; Ronnie Guillet
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

10.  Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants.

Authors:  Nicolas Gregoire; Luc Desfrere; Jean-Christophe Roze; Yves Kibleur; Petra Koehne
Journal:  J Clin Pharmacol       Date:  2008-09-16       Impact factor: 3.126

View more
  15 in total

Review 1.  Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future.

Authors:  Kate O'Hara; Ian M R Wright; Jennifer J Schneider; Alison L Jones; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

Review 2.  Paediatric pharmacokinetics and drug doses.

Authors:  Kate O'Hara
Journal:  Aust Prescr       Date:  2016-12-05

Review 3.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

4.  Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.

Authors:  Stéphanie Leroux; Evelyne Jacqz-Aigrain; Valérie Biran; Emmanuel Lopez; Doriane Madeleneau; Camille Wallon; Elodie Zana-Taïeb; Anne-Laure Virlouvet; Stéphane Rioualen; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

5.  Population pharmacokinetics of gentamicin and dosing optimization for infants.

Authors:  Susanna E Medellín-Garibay; Aída Rueda-Naharro; Silvia Peña-Cabia; Benito García; Silvia Romano-Moreno; Emilia Barcia
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

6.  Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants.

Authors:  Jin A Sohn; Han-Suk Kim; Jaeseong Oh; Joo-Youn Cho; Kyung-Sang Yu; Juyoung Lee; Seung Han Shin; Jin A Lee; Chang Won Choi; Ee-Kyung Kim; Beyong Il Kim; Eun Ae Park
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

Review 7.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

8.  High-dose gentamicin in newborn infants: is it safe?

Authors:  Jon Widding Fjalstad; Einar Laukli; John N van den Anker; Claus Klingenberg
Journal:  Eur J Pediatr       Date:  2013-11-14       Impact factor: 3.183

9.  Special population considerations and regulatory affairs for clinical research.

Authors:  Kristin N Grimsrud; Catherine M T Sherwin; Jonathan E Constance; Casey Tak; Athena F Zuppa; Michael G Spigarelli; Nicole L Mihalopoulos
Journal:  Clin Res Regul Aff       Date:  2015

10.  Population pharmacokinetics of theophylline in adult Chinese patients with asthma and chronic obstructive pulmonary disease.

Authors:  Yanjiao Ma; Ling Xue; Xin Chen; Yingbo Kang; Yong Wang; Liqing Wang
Journal:  Int J Clin Pharm       Date:  2018-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.